When was PreComb founded?

PreComb was founded in 2018 and raised its 1st funding round 3 years after it was founded.

Where is PreComb located?

PreComb is headquartered in Hombrechtikon, Switzerland.

How many employees does PreComb have?

As of Aug 31, 2026, the latest employee count at PreComb is 12.

Is PreComb a funded company?

PreComb is a funded company, having raised a total of $3.72M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 26, 2021.

When was the latest funding round of PreComb?

PreComb's latest funding was a $***** Series A round on Dec 30, 2024, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In Switzerland, the Life Sciences Platforms and Tools sector has seen $42.4M in funding in 2026 to date.

Where does PreComb rank among its competitors?

PreComb ranks 166th amongst 489 active competitors, of which 146 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was GenSight Biologics, which secured $1.96M in Mar, 2026.

Who are the top competitors of PreComb?

PreComb's top competitors include Caris Life Sciences, MedGenome and Geneoscopy. Among them, GenSight Biologics secured the most recent funding round in March, 2026.

PreComb - 2026 Company Profile, Funding & Competitors

PreComb is a series A company based in Hombrechtikon (Switzerland), founded in 2018. It operates as a Provides functional cancer profiling using biomarker analysis. PreComb has raised $3.72M in funding from investors like Kinled Holding, HTGF and FiveT. The company has 489 active competitors, including 146 funded and 98 that have exited. Its top competitors include companies like Caris Life Sciences, MedGenome and Geneoscopy.

Company Details

Provides functional cancer profiling using biomarker analysis. Its assay platform uses biomarkers and genetic profiles and provides information about the best possible proximation of the patient’s response from multiple therapeutic options. It helps a physician for choosing effective therapy for cancer treatment. Its offering is an analysis of biomarkers and genetic profiles for precision medicine.

Website: www.precomb.com/
Social
Email ID: *****@precomb.com

Key Metrics

Founded Year

2018

Location

Hombrechtikon, Switzerland

Stage

Series A

Total Funding

$3.72M in 3 rounds

Latest Funding Round

Series A, Dec 30, 2024, $*****

Investors

Kinled Holding & 6 more

Ranked

166^th among 489 active competitors

Employee Count

12 as on Aug 31, 2026

Similar Companies

Caris Life Sciences & 653 more

View PreComb's full profile

PreComb has raised a total funding of $3.72M over 3 rounds. Its first funding round was on Apr 26, 2021. Its latest funding round was a Series A round on Dec 30, 2024 for $*****. 1 investor participated in its latest round. PreComb has 7 institutional investors.

Here is the list of recent funding rounds of PreComb:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 30, 2024	8364158	Series A	4742333	4161412	3972090	7623238
Oct 04, 2022	2434405	Seed	4185580	1892024	6885760	LongeVC & 1 more
Apr 26, 2021	7718665	Seed	7584862	9487779	HTGF & 2 more	7704750

Access funding benchmarks and valuations. Sign up today!

View details of PreComb's funding rounds and investors

PreComb's employee count trend

PreComb has 12 employees as of Aug 26. Here is PreComb's employee count trend over the years:

Uncover PreComb's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PreComb include Caris Life Sciences, MedGenome and Geneoscopy. Here is the list of Top 10 competitors of PreComb, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
2nd	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
3rd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
5th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
6th	Spear Bio 2021, Boston (United States), Series A	Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers	$49M	Foresite Capital, CDH & 5 others	62/100
7th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
8th	Regulus Therapeutics 2007, San Diego (United States), Acquired	Innovative medicines company reimagining medicine to improve and extend people’s lives	$35M	Ionis Pharmaceuticals, Alnylam & 8 others	62/100
9th	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	61/100
10th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Perceptive Advisors, Fidelity Investments ... & 17 others	61/100
166th	PreComb 2018, Hombrechtikon (Switzerland), Series A	Provides functional cancer profiling using biomarker analysis	$3.72M	BioVaria, HTGF & 5 others	36/100